MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) will report fourth quarter and full year 2025 financial results before market open on March 31, 2026 and host a conference call and webcast at 8:30 a.m. ET.

The company also highlighted platform expansion with a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers, citing non-dilutive funding and downstream commercial revenue potential.

Market Reaction – INKT

+5.81% $9.65

15m delay 9 alerts

+5.81% Since News

$9.65 Last Price

$9.10 $10.12 Day Range

+$2M Valuation Impact

$45M Market Cap

0.1x Rel. Volume

Following this news, INKT has gained 5.81%, reflecting a notable positive market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $9.65. This price movement has added approximately $2M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Earnings date: March 31, 2026 Conference time: 8:30 a.m. ET Conference ID: 6761941 +2 more

5 metrics

Earnings date March 31, 2026 Q4 and full-year 2025 results before market open

Conference time 8:30 a.m. ET Scheduled earnings call and corporate update

Conference ID 6761941 Dial-in identifier for earnings call

US dial-in (646) 307-1963 New York participant number

Toll-free dial-in (800) 715-9871 USA & Canada toll-free number

Market Reality Check

Price: $9.12 Vol: Volume 107,178 is muted v...

low vol

$9.12 Last Close

Volume Volume 107,178 is muted versus 20-day average 836,777 (about 0.13x typical activity). low

Technical Shares at 9.12, trading below 200-day MA of 12.93 and well under the 76.00 52-week high.

Peers on Argus

INKT fell 6.37% while close peers were mixed: ACET -2.18%, ARTV -1.68%, but ALXO...

INKT fell 6.37% while close peers were mixed: ACET -2.18%, ARTV -1.68%, but ALXO +4.00%, HOWL +3.05%, PRLD +0.30%, indicating stock-specific pressure rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Strategic collaboration	Positive	+29.3%	Announced C-Further collaboration on PRAME-targeted TCR-engineered iNKT therapy.
Mar 10	Partner program launch	Positive	+29.3%	C-Further unveiled PRAME-targeted allogeneic iNKT program with MiNK involvement.
Feb 03	New translational data	Positive	+2.2%	Presented allo-iNKT IPF data supporting disease-modifying potential at Keystone Symposia.
Jan 08	Phase 1 trial start	Positive	-1.7%	Announced investigator-sponsored Phase 1 AgenT-797 trial for GvHD prevention.
Nov 20	Preclinical tumor data	Positive	-1.3%	Reported MiNK-215 preclinical data showing potent anti-tumor and TME remodeling.

Pattern Detected

Positive partnership and data updates often aligned with gains, while some positive clinical/preclinical milestones saw modest negative reactions.

Recent Company History

Over the past several months, MiNK highlighted multiple advances in its iNKT platform. A collaboration with C-Further on PRAME‑targeted pediatric oncology coincided with a 29.28% move, and C-Further’s broader pediatric oncology announcement saw the same reaction on Mar 10, 2026. Earlier, new IPF translational data led to a smaller 2.18% rise. In contrast, a Phase 1 GvHD trial start and potent MiNK‑215 preclinical data on Jan 8, 2026 and Nov 20, 2025 drew slight declines, showing occasional divergence even on constructive updates.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$150,000,000 registered capacity

An effective S-3 shelf filed on Nov 7, 2025 allows MiNK to offer up to $150,000,000 in securities, including an ATM program for up to $50,000,000 in common stock, providing financing flexibility for R&D and corporate purposes while introducing potential dilution if utilized.

Market Pulse Summary

The stock is up +5.8% following this news. A strong positive reaction aligns with recent history whe...

Analysis

The stock is up +5.8% following this news. A strong positive reaction aligns with recent history where constructive collaborations and data often coincided with gains, such as the 29.28% move on prior PRAME news. Investors would weigh this enthusiasm against financing flexibility from the $150,000,000 shelf and $50,000,000 ATM capacity, which allow capital raises but may dilute equity if used, and past instances where favorable clinical updates produced only modest or mixed follow-through.

Key Terms

allogeneic, invariant natural killer t (inkt) cell therapies, tcr-engineered, non-dilutive funding, +2 more

6 terms

allogeneic medical

"a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

invariant natural killer t (inkt) cell therapies medical

"pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer"

Invariant natural killer T (iNKT) cell therapies use a specific type of immune cell that combines features of two frontline defenders—T cells and natural killer cells—and are grown or reprogrammed to seek and destroy diseased cells. Think of them as retrained guard dogs taught to recognize particular threats; they matter to investors because successful therapies can offer powerful, potentially durable treatments for cancer and other diseases, but they also carry high clinical, manufacturing and regulatory risk that can strongly affect company value.

tcr-engineered medical

"a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers"

TCR-engineered describes immune cells that have been genetically reprogrammed to carry a specific T-cell receptor, which lets them recognize and attack particular disease markers, most often on cancer cells. For investors, these therapies are important because they represent a precision treatment approach with high upside if effective, but they also carry technical, safety and regulatory risks that can strongly influence a biotech company's valuation and development timeline — think of retraining soldiers to find a hidden enemy, with both potential for decisive wins and costly setbacks.

non-dilutive funding financial

"The collaboration brings non-dilutive funding, meaningful downstream commercial revenue potential"

Non-dilutive funding is money a company raises that does not require issuing new shares or reducing existing owners’ percentage ownership, such as grants, certain loans, contract revenue, or licensing deals. It matters to investors because it lets a company finance growth or research without shrinking shareholder stakes or changing control, much like topping up a car’s gas tank instead of selling part of the car to pay for the trip.

downstream commercial revenue financial

"non-dilutive funding, meaningful downstream commercial revenue potential, and further validation"

Downstream commercial revenue is the money a company earns from the sale and distribution of a product after it has passed development and entered the market, including royalties, distribution fees or percentage-based payments from partners. Investors care because this income reflects real market demand and ongoing cash flow—like receiving a steady commission on every ticket sold once a show goes on—making future earnings and valuation more predictable.

engineered cell therapy medical

"validation of MiNK’s iNKT platform in engineered cell therapy."

Engineered cell therapy uses living cells that have been altered in a lab to perform a specific therapeutic task, such as seeking out and destroying diseased tissue or repairing damaged organs. Think of it as reprogramming a repair crew to do a new job. It matters to investors because these treatments can offer durable, high-value medical benefits but carry big scientific, manufacturing and regulatory risks that drive company valuation and stock swings.

AI-generated analysis. Not financial advice.

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026.

The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio.

The update follows several recent corporate and development milestones, including MiNK’s newly announced collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration brings non-dilutive funding, meaningful downstream commercial revenue potential, and further validation of MiNK’s iNKT platform in engineered cell therapy. The program expands MiNK’s presence across validated tumor antigens and underscores the broader therapeutic and strategic value of its clinically advanced, allogeneic iNKT platform.

The collaboration reflects MiNK’s strategy of expanding its iNKT platform across both clinical-stage programs and engineered cell therapy approaches targeting validated tumor antigens, while leveraging external partnerships to advance programs in a capital-efficient manner.

Conference Participant Dial Information
United States - New York	(646) 307-1963
USA & Canada - Toll-Free	(800) 715-9871
Conference ID -	6761941

Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.

Live event link: https://edge.media-server.com/mmc/p/6xxeh8o5
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

Source: MiNK Therapeutics

FAQ

When will MiNK Therapeutics (INKT) release Q4 and full year 2025 financial results?

MiNK will report Q4 and full year 2025 results before market open on March 31, 2026. According to the company, a conference call and webcast will follow at 8:30 a.m. ET to review results and provide a corporate update.

How can investors join the MiNK Therapeutics (INKT) March 31, 2026 earnings webcast?

Investors can join the live webcast via the company's Events & Presentations page or the provided media-server link. According to the company, a replay will be available on the investor website after the event.

What did MiNK Therapeutics announce about the collaboration with C-Further and University of Southampton?

MiNK announced a collaboration to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. According to the company, the deal brings non-dilutive funding and potential downstream commercial revenue, expanding its engineered iNKT platform.

What topics will MiNK Therapeutics (INKT) cover on the March 31, 2026 call?

The call will cover fourth quarter and full year 2025 financial results plus updates on clinical progress, platform expansion, and strategic initiatives. According to the company, management will review recent corporate and development milestones.

Will the MiNK Therapeutics (INKT) webcast be available after the live event?

Yes, a replay of the webcast will be accessible from the company's Events & Presentations page after the live event. According to the company, the replay link is posted on the investor site for later viewing.

What is the strategic significance of MiNK's PRAME-targeted iNKT program for investors in INKT?

The program broadens MiNK's engineered iNKT pipeline into validated tumor antigens and pediatric oncology. According to the company, the collaboration could validate the platform and enable capital-efficient advancement with non-dilutive funding.